Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
NovoCure Limited - Ordinary Shares (NVCR)
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
novocure.com/investor-relations
Company Research
Source: Business Wire
Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimenCE Mark approval is supported by the Phase 3 LUNAR trial, which demonstrated the first substantial improvement in median overall survival in more than 8 years for this patient populationOptune Lua is a wearable medical device that delivers Tumor Treating Fields (TTFields), a first-of-its-kind therapy for metastatic NSCLC that uses electric fields to kill cancer cells BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) concurrently with immune checkpoint inhibitors or docetaxel who have progressed on or after a platinum-based regimen.“Optune Lua is an innovative and urgently needed new approach for treating metastatic non-s
Show less
Read more
Impact Snapshot
Event Time:
NVCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
News
- Novocure to Present at 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Novocure names Frank Leonard as CEO [Seeking Alpha]Seeking Alpha
- Novocure Appoints Company President Frank Leonard as Chief Executive OfficerBusiness Wire
- Novocure to Participate in 37th Annual Piper Sandler Healthcare ConferenceBusiness Wire
- Novocure to Participate in 2025 Jefferies Global Healthcare ConferenceBusiness Wire
NVCR
Earnings
- 10/30/25 - Beat
NVCR
Sec Filings
- 12/1/25 - Form 8-K
- 11/13/25 - Form SCHEDULE
- 11/7/25 - Form SCHEDULE
- NVCR's page on the SEC website